Abstract: Technology herein relates in part to methods, processes and apparatuses for analyzing nucleic acid sequence reads, where the sequence reads are partial sequence reads having one or more nucleotide species from a subset of the nucleotide species present in a sample nucleic acid at some but not all nucleotide positions of the partial sequence reads or one or more nucleobase classes at some or all nucleotide positions of the partial sequence reads.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations. Provided in certain aspects are systems for analyzing cell-free nucleic acid sequence reads. Provided in certain aspects are systems for detecting a chromosome aneuploidy. Provided in certain aspects are systems for detecting a chromosome aneuploidy based on an analysis of cell-free nucleic acid sequence reads for chromosomes 13, 18, and 21.

Abstract: The technology relates in part to estimating fetal fraction in non-invasive prenatal testing using one or more fragmentomics parameters. In some aspects, the technology relates to estimating fetal fraction according to nucleic acid fragment lengths and sequence motif frequencies.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Technology provided herein relates in part to methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided in part herein are methods and processes that can be used for non-invasive assessment of a genetic variation which can lead to diagnosis of a particular medical condition or conditions. Such methods and processes can, for example, identify dissimilarities or similarities for one or more features between a subject data set and a reference data set, generate a multidimensional matrix, reduce the matrix into a representation and classify the representation into one or more groups. Methods and processes described herein are applicable to data in biotechnology and other fields.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations that make use of nucleic acid fragments from circulating cell free nucleic acid. Also provided herein are methods for partitioning one or more genomic regions of a reference genome into a plurality of portions according to one or more features.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided herein are methods, processes, systems, machines and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided are methods and systems for sample quality control in CNV detection using test samples comprising cell-free nucleic acid fragments originating from a mother and a fetus. The method involves determining an exclusion region defined by at least a fetal fraction limit of detection (LOD) curve. The fetal fraction LOD curve varies with coverage values and indicates minimum values of fetal fractions needed to achieve a detection criterion given different coverages.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations. Also provided herein are methods, processes and apparatuses for determining fetal fraction in a cell-free a sample from a pregnant subject. Also provided herein are methods, processes and apparatuses for determining fetal fraction in a cell-free a sample from a pregnant subject based on a maternal copy number variation. Also provided herein are methods, processes and apparatuses for determining fetal fraction in a cell-free a sample from a pregnant subject based on a maternal microduplication or microdeletion.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations that make use of nucleic acid fragment length information.

Abstract: Techniques are described for identifying a genetic variant in a test sample by comparing sequences reads obtained from the test sample to unique k-mers that are representative of a target genomic region. In one particular aspect, a method is described that includes generating a dictionary of a target genomic region having a set of unique k-mers by: accessing a sequence of the target genomic region, determining a set of k-mers for the target genomic region, comparing the set of k-mers for the target genomic region with one or more sets of k-mers for non-target genomic regions, and selecting the unique k-mers that do not appear in the one or more sets of k-mers for non-target genomic regions. The dictionary can then be used to identify a genetic variant in a test sample by comparing sequences reads obtained from the test sample to the unique k-mers in the dictionary.

Abstract: Methods for non-invasive assessment of genetic variations that make use of nucleic acid fragment length information, in particular length of fragments in circulating cell-free nucleic acids and compares the number of counts from fragments with different length.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: The presently described techniques provide for the use of low-pass sequencing data in the calculation of a polygenic risk score for an individual. As discussed herein, the low-pass sequencing data may be acquired in a context where DNA (e.g., cfDNA) from more than one source is present in the sample and the portion of the DNA attributable to a secondary source may bias the PRS calculation for the primary individual of interest. In one implementation fragment length may be used to derive a function (e.g., a linear function) relating fetal fraction to the respective PRS estimate at each fetal fraction. This function may then be used to calculate the PRS in the absence of a fetal contribution (i.e., at a 0% fetal fraction).

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.

Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations.